Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: "The article states that the costs are “generally … close to $45,000.” The news story notes in a sentence that hip replacement has a success rate of more than 90%, and defines “success” as “relatively pain-free mobility.” The article also clearly states why this new device was developed — to provide longer lifetime use prior to device failure. It quantifies this benefit vaguely, saying the device is ""much more durable"" and lasts ""much longer."" The news story focuses on one main harm—squeaking in hip implants made of ceramic—and provides estimates of its prevalence. A spokesperson for the hip maker points out that hip replacement has other potential risks as well, including infection, dislocation, and leg-length discrepancy. The news story makes it fairly clear that the research it is citing is from cohort studies. The first mention of the prevalence of squeaking in ceramic hip implants appears to cite the highest known estimate—7% of ceramic implants in one study of 143 patients. Only later do readers discover that other studies suggest the prevalence of the problem may be much smaller, from 3% (in a study of 1500 people) to less than 1%. This is not disease mongering, but it could cause some people to fear ceramic hip implants more than may be justified. In addition, the Times article says no squeaking occurred in patients with metal and plastic implants. But a recent 2007 review in the Journal of Bone & Joint Surgery (JBJS) reported that squeaking in similar implants made out of metal and plastic occurred in 4% of patients. (JBJS 2007;89:1874-85) If the JBJS review is accurate, the news story would be misleading. Unfortunately, the JBJS failed to support its own contention with a complete reference. The story cites 4 patients, 4 surgeons, a spokesperson for implant maker Stryker, and a lawyer representing aggrieved patients. All in all, they provide a balance of viewpoints. The story mentions a conflict of interest for one surgeon. It appears that 2 of the patients are clients of the lawyer. The story points out that the alternatives to a ceramic total hip replacement include hip replacements with implants made from metal and plastic. It doesn’t mention whether there are nonsurgical alternatives to hip replacement, but this is beyond the scope of the story. The story does not explicitly state that ceramic hip replacements are approved by the FDA, but with “tens of thousands” implanted, it’s clear that surgeons’ adoption of the devices is widespread. The FDA’s warning to implant maker Stryker about squeaking suggests the devices may not be perfect, but are approved. The story notes that Stryker introduced ceramic hip implants into the U.S. in 2003. The story cites several sources and does not appear to rely solely or largely on a news release."

A: That Must Be Bob. I Hear His New Hip Squeaking.
****
Q: File photo shows a young carer holding the hands of an elderly woman in a residential home for the elderly in Planegg near Munich June 19, 2007. REUTERS/Michaela Rehle The study, reported on Sunday in the journal BioMed Central BMC Neurology, involved 12 patients who had greatly improved language recall shortly after treatment with Enbrel, or etanercept, an anti-inflammatory drug co-marketed by Amgen and Wyeth. “We often see verbal effects within a few minutes of the first dose,” said Dr. Edward Tobinick, director of the Institute for Neurological Research, a private medical group inc., in Los Angeles, who led the study. Tobinick invented and holds several patents on a special method of injecting the drug into the neck. He said he charges anywhere between $10,000 and $40,000 per patient for the treatments. In January, Tobinick’s report on a single patient, and release of a striking video, drew the attention of the Alzheimer’s Association, which released a statement expressing concern. “People with Alzheimer’s and their families may place undue value on this new finding based on the dramatic language used in its description and the apparent immediate effect,” the group said. “We need to see work in other laboratories by scientists without financial interest in the product,” it added. Dr. Sam Gandy, chairman of the Alzheimer’s Association’s medical and science council, said the latest study, done at Tobinick’s clinic, does not offer that independent confirmation. “It’s still not a proper trial,” Gandy said. Tobinick believes the drug may work in the brain by blocking an excess of tumor necrosis factor-alpha or TNF-alpha, which may affect communication in the brain. The study looked at language difficulties, such as in finding words, in 12 patients with mild-to-severe Alzheimer’s disease who were administered etanercept weekly for six months. “There was a significant improvement in the majority of the verbal measures that were studied. The remainder showed a tendency toward improvement, which was not significant,” Tobinick said in a telephone interview. He said the study provides evidence that “excess TNF, in the Alzheimer brain, may offer a new way to address this language dysfunction.”   Tobinick acknowledged the study is limited because people knew they were getting the drug. Alzheimer’s patients in such open-label studies often show improvement. “Placebo effect is an enormous problem in open-label studies,” said Dr. Scott Turner, incoming director of the Memory Disorders Program at Georgetown University Medical Center in Washington. Turner said the true test must come from a more scientifically rigorous double-blind, placebo-controlled, randomized clinical trial. In such studies, patients receive either a dummy treatment or an active agent, and neither the doctor nor the patient knows which. Amgen has also expressed concern about the research, claiming there has been insufficient evidence so far. “This off-label, unapproved treatment, administered by Dr. Edward Tobinick, is not supported nor endorsed by Amgen,” the company said in April on its Web site. A video showing one woman's response to the drug in a sister study can be found at : here

A: Drug restores speech in Alzheimer's; experts worry.
****
Q: The House voted to add insomnia and opioid use disorder to the list of qualifying conditions, though the latter would carry significant restrictions, including a requirement that certifying providers have specialized knowledge in addiction treatment. An earlier version of one of the bills also sought to add anxiety and Lyme disease to the list, but those provisions were removed. Meanwhile, the Senate voted Wednesday against making medical marijuana available for any condition for which treatment is determined to be necessary by a provider. The Senate also voted to further study a bill to legalize recreational marijuana, and there are several new bills on that topic coming up later this session.

A:
House passes bills to expand medical marijuana.
****